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Peroxisome Proliferator Activated Receptor (PPAR)-𝛿 agonists may serve for treating metabolic diseases. However, the effects of
PPAR-𝛿 agonism within the skeletal muscle, which plays a key role in whole-body glucose metabolism, remain unclear. This study
aimed to investigate the signaling pathways activated in the gastrocnemiusmuscle by chronic administration of the selective PPAR-
𝛿 agonist, GW0742 (1mg/kg/day for 16 weeks), in male C57Bl6/J mice treated for 30 weeks with high-fructose corn syrup (HFCS),
themajor sweetener in foods and soft-drinks (15%wt/vol in drinkingwater).Mice fedwith theHFCS diet exhibited hyperlipidemia,
hyperinsulinemia, hyperleptinemia, and hypoadiponectinemia. In the gastrocnemius muscle, HFCS impaired insulin and AMP-
activated protein kinase signaling pathways and reduced GLUT-4 and GLUT-5 expression and membrane translocation. GW0742
administration induced PPAR-𝛿 upregulation and improvement in glucose and lipid metabolism. Diet-induced activation of
nuclear factor-𝜅B and expression of inducible-nitric-oxide-synthase and intercellular-adhesion-molecule-1 were attenuated by drug
treatment. These effects were accompanied by reduction in the serum concentration of interleukin-6 and increase in muscular
expression of fibroblast growth factor-21. Overall, here we show that PPAR-𝛿 activation protects the skeletal muscle against the
metabolic abnormalities caused by chronic HFCS exposure by affecting multiple levels of the insulin and inflammatory cascades.
1. Introduction
In healthy humans, skeletal muscle accounts for ∼70–80%
of the insulin-stimulated glucose uptake, being the major
site of glucose disposal and, thus, exerting a key role in
regulating whole body glucose homeostasis. Accordingly,
understanding changes that occur to this tissue during
obesity and diabetes development is crucial to elucidate the
underlying causes of insulin resistance and to reveal new
targets for its treatment. Insulin resistance in skeletal muscle
has long been recognized as a characteristic feature of type
2 diabetes and plays a major role in the pathogenesis of
the disease [1]. Although several epidemiological data have
shown that the consumption of added sugars as ingredients
in processed or prepared foods and caloric beverages has
dramatically increased over the last decades, most of the
experimental studies investigating the development of insulin
resistance in the skeletal muscle have been based on genetic
manipulation or use of high fat diets [2–4]. In contrast, the
molecular mechanisms underlying the detrimental effects of
sugar, mainly those on skeletal muscle, are not completely
understood. In the present study, we used a previously
developedmousemodel of chronic exposure to high-fructose
corn syrup (HFCS) [5] to investigate the deleterious effects
of high sugar intake on skeletal muscle. HFCS syrup, used
as an ingredient in processed or prepared foods and caloric
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beverages, is synthesized by refining corn starch, contains
55% fructose and 42% glucose and to date accounts for over
40% of all added caloric sweeteners [6].
The Peroxisome Proliferator Activated Receptor (PPAR)
superfamily of transcription factors, that includes the iso-
forms PPAR-𝛼, PPAR-𝛿, and PPAR-𝛾, has been widely shown
to exert crucial roles in energy homeostasis regulation and
glucose metabolism. PPAR isoforms display tissue-specific
expression and gene-regulatory profiles. PPAR-𝛿, one of
the most promising pharmacological target implicated in
obesity-associated insulin resistance [7], is highly expressed
in skeletal muscle, at 10- and 50-folds higher levels compared
with PPAR-𝛼 and PPAR-𝛾, respectively [8]. However, its
potential effects in affecting skeletal muscle glucose intake
and insulin sensitivity are only now being elucidated. Schuler
et al. [9] showed that mice in which PPAR-𝛿 is selectively
ablated in skeletal myocytes exhibit fiber-type switching,
obesity, and type 2 diabetes. Besides, a very recent paper
has suggested that the improvement of glucose homeostasis
by angiotensin receptor blockers in hypertensive patients
involves a selective PPAR-𝛿 activation in the skeletal muscle
[10]. So far, the exact molecular mechanisms underlying the
observed PPAR-𝛿-induced changes have not yet been deter-
mined. Hence, the present study aimed to determine whether
chronic administration of the selective PPAR-𝛿 agonist
GW0742 in HFCS-fed mice may ameliorate the impairment
of signaling pathways triggered in skeletal muscles by chronic
high sugar intake. Several studies have revealed that a large
number of muscle-derived secretory cytokines (collectively
termed myokines) can act locally in an autocrine/paracrine
manner, linking skeletal muscle to regulation of physiological
processes in other tissues. We have, thus, also investigated
whether PPAR-𝛿 agonism may affect the serum levels of the
well-known myokine interleukin-6 (IL-6) and the muscular
expression of a member of the fibroblast growth factor (FGF)
superfamily, FGF-21, a recently identified myokine involved
in the interorgan communication [11]. To further extend our
investigation on the ability of PPAR-𝛿 agonism to modulate
inflammatory pathways involved in local insulin resistance
pathogenesis, the effects of PPAR-𝛿 activation on nuclear
translocation of the transcription nuclear factor-kappaB (NF-
𝜅B) and expression of its target genes have also been studied.
2. Materials and Methods
2.1. Animals and Diets. Four-week-old male C57Bl6/J mice
(Harlan-Italy; Udine, Italy) were housed in a controlled
environment at 25 ± 2∘C with alternating 12-h light and dark
cycles. They were provided with a Piccioni pellet diet (n. 48,
Gessate Milanese, Italy) and water ad libitum. All the animals
were fed with a normal pellet diet for 1 week prior to the
experiment. The animals were then allocated to two dietary
regimens, chow diet and normal drinking water (control)
or a chow diet and 15% (wt/vol) HFCS solution in drinking
water (HFCS) for 30 weeks. All diets contained a standard
mineral and vitamin mixture. The concentration of HFCS
solution as well as the period of dietary manipulation was
chosen according to previous animal studies investigating the
metabolic effects of long-term (6-7 months) access to HFCS.
Body mass, intake of water, and food were recorded weekly.
Animal care was in compliance with Italian regulations on
the protection of animals used for experimental and other
scientific purposes (DM 116/92), and the experiment was
approved by the Turin University Ethics Committee.
2.2. Drug Administration. After the initial period of 14 weeks
of dietary manipulation, each of the two diet groups (control
and HFCS diet) was further subdivided to obtain four
different treatment groups: chow diet and normal drinking
water (control, 𝑛 = 10), chow diet supplemented with
GW0742 (1mg/kg/day) and normal drinking water (control+
GW, 𝑛 = 6), chow diet and 15% (wt/vol) HFCS solution in
drinking water (HFCS, 𝑛 = 10), and chow diet supplemented
with GW0742 (1mg/kg/day) and 15% (wt/vol) HFCS solution
in drinking water (HFCS + GW, 𝑛 = 10). The drug was
daily administered with the food for the last 16 weeks, and
the mice were allowed to continue to feed on their respective
diets until the end of the study. GW0742 is a highly potent
and selective PPAR-𝛿 agonist (murine EC
50
: 28 nM for PPAR-
𝛿; 8,900 nM for PPAR-𝛼; >10,000 nM for PPAR-𝛾), with an
acceptable pharmacokinetic profile and activity in vivo [12].
The dose and the kinetics of administration were chosen
based on those we have previously shown to improve glucose
tolerance and insulin sensitivity in vivo [5].
2.3. Oral Glucose Tolerance Test (OGTT). One day before the
mice were due to be killed, the OGTT was performed after
a fasting period of 6 h by administering glucose (2 g/kg) by
oral gavage. Once before administration and 15, 30, 60, 90,
120, and 150min afterward, blood was obtained from the
saphenous vein, and glucose concentration was measured
with a conventional Glucometer (Accu-Check Compact kit,
Roche Diagnostics Gmbh, Mannheim, Germany).
2.4. Blood Biochemical Analysis. After 16 weeks from the
start of the drug treatment (i.e., after 30 weeks of dietary
manipulation), the mice were anaesthetised with i.p. injec-
tion (30mg/kg) of Zoletil 100 (Laboratories Virbac, France)
and killed by aortic exsanguination. Blood samples were
collected, and plasma was isolated. Glycemia was measured
using the Accu-Check Compact kit. The serum lipid profile
was determined by measuring the content of triglycerides,
total cholesterol, high-density lipoprotein (HDL), and low
density lipoprotein (LDL) by standard enzymatic procedures
using reagent kits (Hospitex Diagnostics, Florence, Italy).
Plasma leptin and adiponectin levels were measured using
enzyme-linked immunosorbent assay (ELISA) kits (Leptin
and Adiponectin Mouse ELISA Kits, Abcam, Cambridge
UK).The gastrocnemius muscle and epididymal fat were iso-
lated, weighed, rapidly freeze-clamped with liquid nitrogen,
and stored at −80∘C.
2.5. Tissue Extracts. Gastrocnemius extracts were prepared
using the Meldrum method [13] with modification. Briefly,
gastrocnemius were homogenised at 10%(w/v) in a Potter-
Elvehjem homogenizer (Wheaton, NJ, USA) using a
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homogenisation buffer containing 20mM HEPES, pH
7.9, 1mM MgCl
2
, 0.5mM EDTA, 1mM EGTA, 1mM
dithiothreitol (DTT), 0.5mM phenylmethylsulfonyl fluoride
(PMSF), 5 𝜇g/mL aprotinin, and 2.5𝜇g/mL leupeptin.
Homogenates were centrifuged at 4000 RPM at 4∘C for
5min. Supernatants were removed and centrifuged at
14000 RPM at 4∘C for 40 minutes to obtain the cytosolic
fraction. The pelleted nuclei were resuspended in an
extraction buffer and centrifuged at 14000 RPM for 20
minutes at 4∘C. The supernatants thus obtained, containing
nuclear proteins, were carefully removed. The amount of
proteins contained in the cytosolic and nuclear fraction
was determined using a BCA protein assay following the
manufacturers’ instructions. Samples were stored at −80∘C
until use.
2.6. Skeletal Muscle Triglyceride Level. Skeletal muscle trigly-
cerides were extracted from gastrocnemius homogenates and
assayed using reagent kits according to the manufacturer’s
instructions (TriglycerideQuantificationKit, AbnovaCorpo-
ration, Aachen, Germany).
2.7. Western Blot Analysis. About 60𝜇g of total proteins was
loaded for western blot experiments. Proteins were separated
by 8% sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to a polyvinyldene
difluoride (PVDF) membrane, which was then incubated
with a primary antibody (rabbit anti-PPAR-𝛿, dilution 1 : 500;
rabbit antitotal GSK-3𝛽, dilution 1 : 200; goat anti-pGSK-3𝛽
Ser9, dilution 1 : 200; rabbit antitotal Akt, dilution 1 : 1000;
mouse anti-pAkt Ser473, dilution 1 : 1000; goat anti-ICAM-
1, dilution 1 : 500; rabbit antitotal IRS-1, dilution 1 : 200; goat
anti-pIRS-1 Ser307, dilution 1 : 200; rabbit anti-GLUT-4, dilu-
tion 1 : 2000; rabbit anti-GLUT-5, dilution 1 : 100; rabbit anti-
iNOS, dilution 1 : 200; rabbit anti-NF-𝜅B dilution 1 : 1000;
rabbit antitotal AMPK, dilution 1 : 1000; rabbit anti-pAMPK
Thr172, dilution 1 : 1000; rabbit antitotal ACC, dilution 1 : 500;
rabbit anti-pACC Ser79, dilution 1 : 1000; rabbit anti-CPT-1,
dilution 1 : 200). Blots were then incubated with a secondary
antibody conjugated with horseradish peroxidase (dilution
1 : 10000) and developed using the ECL detection system.The
immunoreactive bands were visualised by autoradiography
and the density of the bands was evaluated densitometrically
using Gel-Pro Analyzer 4.5, 2000 software (Media Cybernet-
ics, Silver Spring, MD, USA). The membranes were stripped
and incubated with tubulin monoclonal antibody (dilution
1 : 5000) and subsequently with an anti-mouse antibody
(dilution 1 : 10000) to assess gel-loading homogeneity.
2.8. Immunohistochemistry. Immunohistochemical staining
was performed on 10-𝜇m acetone fixed cryostatic sections of
gastrocnemius. Nonspecific binding sites were blocked for 1 h
with 3% BSA in PBS. For immunodetection of glucose trans-
porter type-4 (GLUT-4), sections were incubated overnight
with rabbit anti-GLUT-4 antibody (Abcam), dilution 1 : 200,
and for 1 hour with goat anti-rabbit IgG-HRP conjugated
secondary antibody (Bio-Rad Laboratories, Hercules, CA,
USA). For detection of glucose transporter type 5 (GLUT-5),
sections were incubated overnight with rabbit anti-GLUT-5
antibody (Abcam), dilution 1 : 50, for 1 hour with swine anti-
rabbit IgG-biotinylated secondary antibody (Dako, Glostrup,
Denmark), and for 1 hour with Streptavidin HRP conjugate
(Southern Biotech, Birmingham, AL, USA). The specific
staining was detected with diaminobenzidine (DAB, Sigma-
Aldrich), and sections were visualized with Olympus-Bx4I
microscope connected by a photographic attachment (Carl
Zeiss, Oberkochen, Germany). For each antibody, a negative
control was included in which the primary antibody was
replaced with a nonimmune isotypic control antibody.
2.9. Determination of IL-6 and FGF-21. Serum levels of IL-
6 and FGF-21 levels in gastrocnemius homogenates were
measured by ELISA according to the manufacturer’s instruc-
tions (Mouse FGF-21 and IL-6 ELISA kits, R&D Systems,
Abingdon, UK).
2.10. Materials. Unless otherwise stated, all compounds were
purchased from the Sigma-Aldrich Company Ltd. (St. Louis,
MO, USA). The BCA Protein Assay kit and SuperBlock
blocking buffer were from Pierce Biotechnology Inc. (Rock-
ford, IL, USA), and PVDF was from the Millipore Corpora-
tion (Bedford, Massachusetts, USA). Antibodies were from
Cell-Signaling Technology (Beverly, MA, USA), Santa Cruz
Biotechnology (Santa Cruz, CA, USA), and Abcam (Cam-
bridge, CB, UK). The anti-mouse, anti-rabbit, and anti-goat
horseradish peroxidase-linked antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), and Luminol
ECL was from PerkinElmer (WalthamMassachusetts, USA).
2.11. Statistical Analysis. All values in both the text and
figures are expressed as mean ± SD for n observations.
One-way analysis of variance with Dunnett’s post-hoc test
was performed using the GraphPad Prism version 4.02 for
Windows (GraphPad Software, San Diego, California, USA),
and 𝑃 values below 0.05 were considered as significant.
3. Results
3.1. Effects of HFCSDiet and GW0742 Administration on Body
Mass Change, Food Intake, and Blood Parameters. After 30
weeks of dietary manipulation, mice on HFCS group had
significantly higher body mass than the control group, with
an increase in body mass over 30% (36.00 ± 1.41 g versus
32.25 ± 1.67 g; 𝑃 < 0.01), whereas GW0742 administration
induced a slight but not significant reduction in body mass
(35.00 ± 2.83 g). Epididymal fat mass was increased by HFCS
manipulation in comparison to control diet (4.22 ± 0.35%
body mass versus 3.66 ± 0.29% body mass; 𝑃 < 0.01), and
values were reduced to the control level by drug administra-
tion (3.86 ± 0.33% body mass). In contrast, neither dietary
manipulation nor drug treatment affected gastrocnemius
mass (% body mass: 0.97 ± 0.19 control, 0.92 ± 0.09 HFCS,
and 0.92 ± 0.06 HFCS + GW). As we previously reported
[5], the HFCS diet caused a significant increase in serum
triglycerides, total cholesterol, and LDL concentrations and a
marked decrease in the HDL levels. GW0742 administration
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reverted the deleterious effects of HFCS diet on the serum
lipid profile. Interestingly, theHFCSdiet significantly affected
insulin sensitivity. A significant increase in serum insulin
levels was observed in mice of HFCS group compared to
controlmice (2.26±0.51 𝜇g/L versus 1.27±0.07 𝜇g/L), and this
increase was almost completely abolished by GW0742 (1.51±
0.46 𝜇g/L). Fasting glucose concentrations were elevated in
serum of HFCS animals in comparison to control animals
(103.4 ± 12.0mg/dL versus 78.7 ± 0.3mg/dL) and reduced
to control levels by GW0742 (81.3 ± 10.9mg/dL). Moreover,
HFCS mice showed a significant impairment in glucose
tolerance to exogenously administered glucose. Although all
the groups reached a glycemic peak at 15min postglucose
challenge (control: 223.1 ± 12.0mg/dL; HFCS: 212.7 ±
7.3mg/dL; HFCS+GW: 198.8 ± 10.3mg/dL), glycemic levels
at 30–60min post glucose challenge in HFCS-fed mice were
higher than those recorded in the control group (30min:
182.9±8.3mg/dL versus 129.4±8.0mg/dL, 𝑃 < 0.05; 60min:
130.7 ± 10.3mg/dL versus 96.8 ± 4.0mg/dL, 𝑃 < 0.05).
GW0742 significantly (𝑃 < 0.05) improved glucose tolerance
in HFCS-fed mice, showing significantly reduced glucose
concentrations at both 30 and 60min postglucose challenge
(89.7 ± 5.2mg/dL and 86.7 ± 4.3mg/dL, resp.).
Data on the effects of dietary manipulation and chronic
GW0742 treatment on serum levels of IL-6, adiponectin, and
leptin are reported in Table 1. The experimental diet caused
a more than fourfold increase in serum IL-6 concentrations,
whereas GW0742 administration significantly decreased the
IL-6 levels. Adiponectin and leptin showed different patterns:
in fact, the level of adiponectin in HFCSmice was lower than
in control mice, while that of leptin increased versus controls.
When GW0742 was administered to HFCS mice there was
a significant increase (𝑃 < 0.01) in the adiponectin levels
associated with a significant decrease (𝑃 < 0.01) in leptin
serum concentration.
It must be noted that in control mice GW0742 had no
significant effect on any of the previously describedmetabolic
parameters.
3.2. Effect of GW0742 on Skeletal Muscle PPAR-𝛿 Expression.
As shown in Figure 1, HFCS diet did not affect PPAR-
𝛿 protein level expression in the mouse gastrocnemius.
In contrast, daily administration of GW0742 resulted in a
twofold increase in expression of its pharmacological target,
withmaximumeffect in the presence of dietarymanipulation.
3.3. The Effects of HFCS Diet on Insulin Signal Transduction
Were Reverted by GW0742 Administration. The HFCS diet
did not alter the protein expression of IRS-1, Akt, or GSK-
3𝛽 compared to the control group. However, HFCS caused
a marked increase in Ser307 phosphorylation of IRS-1 in
parallel with reduced Ser473 phosphorylation of Akt (Figures
2(a) and 2(b)). Ser9 phosphorylation of GSK-3𝛽, a down-
stream target of Akt, was also reduced in the presence of
HFCS (Figure 2(c)), suggestive of impaired insulin signaling
downstream of IRS-1. Most notably, GW0742 significantly
attenuated all the effects of HFCS on IRS-1, Akt, and GSK-3𝛽
phosphorylation, measured at the steady state.
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Figure 1: Effects of dietary manipulation and GW0742 treat-
ment on PPAR-𝛿 expression in the mouse gastrocnemius. Protein
expression was measured by western blot analysis in gastrocnemius
homogenates of mice fed with a standard (control) or HFCS
diet (HFCS) in the absence or presence of GW0742 treatment
(1mg/kg/day) (control+GW; HFCS+GW). Densitometric analysis
of the bands is expressed as relative optical density (O.D.), corrected
for the corresponding tubulin, and normalized using the related
control band. Data are means ± SD of three separate experiments.
∗
𝑃 < 0.01 versus HFCS.
3.4. Effects of HFCS Diet and GW0742 Treatment on GLUT-
4 and GLUT-5 Expression and Translocation. In compari-
son to control animals, GLUT-4 expression was reduced
in the gastrocnemius of HFCS mice, without reaching a
statistical significance, and increased following drug treat-
ment (Figure 3(a)). Similarly, the HFCS diet markedly
reduced GLUT-5 expression, whereas GW0742 administra-
tion resulted in a significant increase in GLUT-5 expression
(Figure 3(c)). Notably, GW0742 treatment not only increased
carriers expression levels but also induced a significant mem-
brane translocation, thus increasing muscle glucose uptake
(Figures 3(b) and 3(d)).
3.5. Effects of HFCS Diet and GW0742 Treatment on Skeletal
Muscle Triglyceride Content and AMPK/ACC and CPT-1 Sig-
naling Pathway. The triglyceride content was doubled in the
gastrocnemius ofHFCSmice in comparisonwith control ani-
mals, whereas skeletal muscle triglyceride accumulation was
significantly reduced by GW0742 administration (Figure 4).
Changes in the phosphorylation/activation of the AMP-
activated protein kinase (AMPK)/acetyl-CoA carboxylase
(ACC) system, whose central role in the regulation of
cellular lipid homeostasis is well known, were evalu-
ated by immunoblotting experiments on gastrocnemius
homogenates. As reported in Figure 5, there was no signifi-
cant effect of HFCS feeding or drug treatment on total AMPK
and ACC protein content. In contrast, chronic HFCS expo-
suremarkedly reducedThr172 phosphorylation of AMPK and
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Table 1: Effects of chronic in vivo treatment with GW0742 on mouse blood parameters after 30 weeks of dietary manipulation.
Control (𝑛 = 10) Control + GW0742 (𝑛 = 6) HFCS (𝑛 = 10) HFCS + GW0742 (𝑛 = 10)
IL-6 (pg/mL) 20.80 ± 2.11 18.90 ± 4.22 91.55 ± 16.47∗ 28.80 ± 7.99§
Adiponectin (𝜇g/mL) 4.53 ± 0.23 4.75 ± 0.46 1.93 ± 0.08∗ 3.69 ± 0.43∗§
Leptin (pg/mL) 206.65 ± 18.77 198.07 ± 22.17 446.67 ± 52.61∗ 266.12 ± 41.21∗§
HFCS: high-fructose corn syrup; IL-6: interleukin-6.
Data are means ± S.D.
∗
𝑃 < 0.01 versus Control.
§
𝑃 < 0.01 versus HFCS.
Control Control + GW HFCS HFCS + GW
0
1
2
3
Total IRS-1
fo
ld
s t
o 
co
nt
ro
l (
O
.D
.)
Se
r3
07
IR
S-
1/
to
ta
l I
RS
-1
Ser307 IRS-1
∗
∗ ∗
(a)
Control Control + GW HFCS HFCS + GW
0
1
2
3
Total Akt
fo
ld
s t
o 
co
nt
ro
l (
O
.D
.)
Se
r4
7
3
A
kt
/to
ta
l A
kt
Ser473 Akt
∗
∗
∗
(b)
Control Control + GW HFCS HFCS + GW
0
1
2
3
∗
∗
∗
Total GSK-3𝛽
Ser9GSK-3𝛽
fo
ld
s t
o 
co
nt
ro
l (
O
.D
.)
Se
r9
G
SK
-3
𝛽
/to
ta
l G
SK
-3
𝛽
(c)
Figure 2: Effects of GW0742 treatment on insulin signal transduction in the gastrocnemius of mice fed with HFCS diet. Total IRS-1 protein
expression and Ser307 phosphorylation (a), total Akt protein expression and Ser473 phosphorylation (b), and total GSK-3𝛽 protein expression
and Ser9 phosphorylation (c) were analyzed by western blot on the gastrocnemius homogenates obtained from mice fed with a standard
(control) or HFCS diet (HFCS) for 30 weeks and treated with GW0742 (1mg/kg/day) added during the last 16 weeks (control +GW; HFCS+
GW). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding tubulin contents,
and normalized using the related control band. The data are means ± SD of three separate experiments. ∗𝑃 < 0.01 versus HFCS.
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Figure 3: Effects of two dietary regimens either normal (control) or a diet enriched with 15%HFCS solution (HFCS) onGLUT-4 andGLUT-5
expression (resp., (a) and (c)) and membrane translocation (resp., (b) and (d), original magnification: 400x) in the gastrocnemius of mice
treated with GW0742 (1mg/kg/day, control +GW; HFCS +GW). Densitometric analysis of the bands is expressed as relative optical density
(O.D.), corrected for the corresponding tubulin, and normalized using the related control band. Data are means ± SD of three separate
experiments. ∗𝑃 < 0.01 versus HFCS.
its substrate Ser79 ACC. Interestingly, GW0742 treatment led
to a robust increase in phosphorylation of both AMPK and
ACC in HFCS-fed mice (Figures 5(a) and 5(b)). The effects
of PPAR-𝛿 agonism on fatty acid oxidation in skeletal muscle
cells are further indicated by the significant increase in the
protein expression of carnitine palmitoyl transferase-1 (CPT-
1) elicited by GW0742 in HFCS-fed mice (Figure 5(c)).
3.6. Effects of HFCS Diet and GW0742 Treatment on NF-𝜅B
Activation, ICAM-1, and iNOS Expression. To investigate the
muscle inflammatory response induced by HFCS-diet and
the intracellular signaling pathway(s) that might be involved
in the protective mechanisms evoked by GW0742, we firstly
evaluated the effects on NF-𝜅B activation. When compared
to control mice, HFCS mice developed significant increase
in the nuclear translocation of the p65 NF-𝜅B subunit in
the mouse gastrocnemius, indicating the activation of this
transcriptional factor (Figure 6(a)). Treatment with GW0742
resulted in a significant reduction in nuclear translocation of
p65 and, hence, in the activation of NF-𝜅B. The intercellular
adhesion molecule-1 (ICAM-1), whose role in the recruit-
ment of neutrophils is widely accepted, was slightly detected
in the gastrocnemius of control animals, whereas its expres-
sion was dramatically increased by HFCS diet (Figure 6(b)).
As shown in Figure 6(c), also the expression of the inducible
nitric oxide synthase (iNOS) was increased in the presence
of dietary manipulation. Interestingly, these changes were
suppressed by GW0742 administration, as evidenced by
densitometric analysis of the related autoradiograms.
3.7. Effects of HFCS Diet and GW0742 Treatment on Skeletal
Muscle FGF-21 Production. The beneficial effects of PPAR-𝛿
activation were associated with a dramatic increase of FGF-
21 production in the mouse gastrocnemius. As shown in
Figure 7, in comparison to control mice (46.45 ± 1.13 pg/mg
protein), HFCS diet did not affect the production of this
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Figure 4: Triglyceride content in gastrocnemius of mice fed with
a standard diet (control) or a HFCS diet (HFCS) for 30 weeks
and treated with GW0742 (1mg/kg/day) added during the last 16
weeks (control + GW; HFCS + GW). Data are means ± SD of eight
animals/group. ∗𝑃 < 0.01 versus HFCS.
myokine (49.38 ± 4.12 pg/mg protein), whereas GW0742
treatment induced a twofold increase (87.08 ± 6.37 pg/mg
protein).
4. Discussion
In agreement with previous observations [14, 15], the present
study shows that chronic exposure to the most widely
used added sugar HFCS caused a significant increase in
body mass associated with increases in serum levels of
triglycerides, LDL-cholesterol, glucose, insulin, IL-6, leptin,
and hypoadiponectinemia. Using the same experimental
protocol here reported, we have recently demonstrated that
the molecular mechanism underlying the deleterious effects
of HFCS involves the hepatic upregulation of fructokinase,
the main fructose-metabolizing enzyme, which may account
for the increase in serum levels of free fatty acids and
hyperuricemia [5]. We also reported that the documented
increase in serum uric acid level significantly contributed
to the development of chronic kidney injury. Interestingly,
we demonstrated that chronic administration of the PPAR-𝛿
ligand GW0742 exerted beneficial effects by preventing the
upregulation of fructokinase in the liver and activation of
the inflammatory signaling complex NLRP3 inflammasome
in the kidney. Despite these preliminary data, so far, there
are no studies on the effects of long-term exposure to HFCS,
the major sweetener added to beverages and food, on skeletal
muscle, which is a major site of postprandial glucose disposal
and is therefore one of the insulin-sensitive tissuesmost likely
to manifest early signs of insulin resistance. Here, we investi-
gated (i) the mechanisms underlying metabolic disturbances
in skeletal muscle of mice exposed for 30 weeks to high
intake of HFCS and (ii) the local effects evoked by PPAR-𝛿
chronic activation.The sugar was added to the drink water at
a concentration that covers 10% of the daily caloric intake,
corresponding to the average energy intake in the form of
ingested sweeteners in the western diet. We documented the
HFCS-induced alteration in the insulin signal transduction
pathway, as shown by the impaired phosphorylation of IRS-
1 protein as well as of the downstream key insulin signaling
molecules, Akt, and GSK-3𝛽, an Akt substrate [16]. This is
in keeping with previous studies showing that IRS-1 serine
phosphorylation can interfere with subsequent Akt andGSK-
3𝛽 phosphorylation, disrupting insulin signal transduction
[17]. In our experimental model, oral administration of the
selective PPAR-𝛿 agonist GW0742 was associated with a
significant improvement of the defective insulin signaling
in the skeletal muscle, which may account at least in part
for the changes in serum lipid profile and insulin sensitivity.
As the inhibition of GSK-3𝛽 evokes an increase in the
glycogen synthesis [18, 19], we may speculate that GW0742
administration modulates muscle glycogen storage through
inactivation of GSK-3𝛽. Although no direct evidence of
drug treatment on glucose storage has been reported in
our study, we documented the effects of chronic PPAR-
𝛿 activation on glucose transporters expression and distri-
bution. Specifically, we found that PPAR-𝛿 activation by
GW0742 evoked an increase in expression of GLUT-4, the
most abundant glucose transporter isoform in skeletalmuscle
[20], and its translocation from intracellular compartments
to the plasma membrane, thus facilitating glucose transport.
Similarly, GLUT-5, the fructose carrier with low capacity to
transport glucose [21], was scarcely detectable in the gastroc-
nemius muscle of HFCS-fed mice, and its expression and
membrane translocation were enhanced by chronic PPAR-
𝛿 activation. Because fructose is highly present in the HFCS
diet and contributes to carbohydrate metabolism in muscle
[22], the increase in GLUT-5 may favor a better utilization
of fructose supplied in the diet. In any case, the reduction in
GLUT-4 and GLUT-5 expression and translocation detected
in the HFCS group could represent an adaptation to the
chronic exposure to a sugar-enriched diet, while the increases
in these carrier isoforms in the presence of the selective
PPAR-𝛿 agonist GW0742 may account, at least in part, for
the improvement in insulin-induced muscle glucose uptake.
Recent data have shown that Akt inhibitors or dominant-
negative Akt constructs regulate the translocation, targeting,
and fusion of GLUT-4-containing vesicles [23, 24]. Sim-
ilarly, IRS-1 phosphorylation has been reported to affect
GLUT-4 translocation and subsequent glucose uptake in
mouse skeletal myocytes [25]. We may, thus, speculate that
the beneficial effects of the PPAR-𝛿 ligand GW0742 are
secondary to activation of the IRS-1/Akt/GSK-3𝛽 pathway.
This is also supported by previous findings showing that
the chronic administration of GW0742 in rats results in
phosphoinositide-dependent kinase phosphorylation and,
hence, increased Akt phosphorylation [26]. Another enzyme
complexwhich could be involved inPPAR-𝛿metabolic effects
within the skeletal muscle is AMPK, a serine/threonine
protein kinase that has emerged as a key player in both
lipid and glucose metabolism in skeletal muscles [27, 28].
In mouse C2C12 myotubes, AMPK activation potentiated
insulin action by reducing IRS-1 serine phosphorylation [29],
while reduced muscle AMPK activity has been reported
to aggravate muscle insulin resistance following a high-fat
diet over 30 weeks [30]. In agreement with these obser-
vations, we found that GW0742 increased phosphorylation
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Figure 5: Effects of GW0742 treatment on AMPK/ACC phosphorylation and CPT-1 expression in the gastrocnemius of mice fed with HFCS
diet. Total AMPK protein expression andThr172 phosphorylation (a), total ACC protein expression and Ser79 phosphorylation (b), and CPT-1
expression (c) were analyzed by western blot on the gastrocnemius homogenates obtained from mice fed with a standard (control) or HFCS
diet (HFCS) for 30 weeks and treated with GW0742 (1mg/kg/day) added during the last 16 weeks (control+GW;HFCS+GW). Densitometric
analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding tubulin contents, and normalized using
the related control band. The data are means ± SD of three separate experiments. ∗𝑃 < 0.01 versus HFCS.
of Thr172 regulatory site on AMPK which, in turn, causes
ACC phosphorylation. When ACC is inactive (phosphory-
lated form), a fall in malonyl-coenzyme A occurs, which
disinhibits CPT-1 and increases mitochondrial import and
oxidation of long-chain fatty acids [31]. Our data demonstrate
that chronic exposure to GW0742 administration increased
skeletal muscle CPT-1 expression, thus shunting toward fatty
acid oxidation, and this effect was associated with reduced
triglyceride accumulation. These findings suggest that the
beneficial effects evoked by the PPAR-𝛿 agonist GW0742 are
at least partially dependent on AMPK activation. The direct
involvement of PPAR-𝛿 agonism inmediating improvements
in muscle insulin sensitivity and lipid metabolism is also
confirmed by results showing that PPAR-𝛿 is expressed in the
gastrocnemius of both control andHFCS-fedmice and, more
importantly, that its expression is substantially increased by
chronic administration of GW0742, thus suggesting that the
observed drug effects are due to a ligand-dependent PPAR-
𝛿 activation. This is consistent with previous works showing
that PPAR-𝛿 activation is involved in regulating myogenesis
[32–35]. In search of the mechanism(s) underlying the pro-
tective action of GW0742, we investigated whether PPAR-𝛿
activation may affect the local inflammatory response associ-
ated with muscular metabolic injury. Although PPAR-𝛿 has
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Figure 6: Effects of dietary manipulation and GW0742 treatment on NF-𝜅B p65 translocation (a), ICAM-1 (b) and iNOS (c) protein
expression in themouse gastrocnemius. Protein expression wasmeasured byWestern blot analysis in gastrocnemius homogenates ofmice fed
with a standard (control) or HFCS diet (HFCS) in the absence or presence of GW0742 treatment (1mg/kg/day) (control+GW; HFCS+GW).
Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding tubulin contents, and
normalized using the related control band. NF-𝜅B p65 subunit levels in cytosolic and nuclear fractions are expressed as nucleus/cytosol ratio
normalized using the related control band. Data are means ± SD of three separate experiments. ∗𝑃 < 0.01 versus HFCS.
been implicated in the regulation of systemic inflammatory
responses associated with metabolic dysregulation [7], so
far, reports on anti-inflammatory effects of PPAR activation
in skeletal muscle are rather scarce. Here, we show for the
first time that in the skeletal muscle GW0742 reverts the
diet-induced increase in the nuclear translocation of NF-𝜅B
p65, a transcriptional factor that plays an important role in
regulating the transcription of a number of genes, especially
those involved in producing mediators of local and sys-
temic inflammation (such as cytokines, chemokines, and cell
adhesion molecules). This observation is in agreement with
previous studies reporting that PPAR-𝛿 activation induces the
physical interaction between PPAR-𝛿 and the p65 subunit
of NF-𝜅B and reduced the LPS-induced degradation of the
inhibitory protein “Inhibitor of kappa B,” thus preventingNF-
𝜅B activation [36, 37]. The reduction of NF-𝜅B activation by
GW0742 treatment may account for the observed reduction
in the serum levels of IL-6, which is known to be mostly
released from skeletal muscle, and in the local expression
of the NF-𝜅B-dependent proteins iNOS and ICAM-1, whose
role in the development of insulin resistance has been recently
documented [38, 39]. As several studies have reported an
association between GSK-3𝛽 and NF-𝜅B activity [40], we
might speculate that PPAR-𝛿 activation phosphorylates, and
hence, activates the Akt pathway, which in turn phospho-
rylates, and hence, inhibits GSK-3𝛽, presumably resulting
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Figure 7: Fibroblast growth factor-21 (FGF-21) levels were analyzed
by ELISA in gastrocnemius homogenates ofmice fedwith a standard
(control) or HFCS diet in the absence or presence of GW0742
(1mg/kg/day). Data aremeans±SD of five animals/group. ∗𝑃 < 0.01
versus HFCS.
in the inhibition of NF-𝜅B and, in turn, NF-𝜅B-dependent
proinflammatory gene transcription. Although this cross
talk among different signaling pathways by pharmacological
PPAR-𝛿 modulation is intriguing, it must be stressed, how-
ever, that the lack of direct experimental evidence of a causal
relationship between the improved local and systemic insulin
sensitivity and the treatment-induced reduction of NF-𝜅B
activation in our experimental model limit the interpretation
of the molecular mechanism(s) underlying our findings.
One of the most recently identified mediators that facilitates
organ cross talk and the related control of impaired glucose
homeostasis in metabolic diseases is a member of the FGF
family, FGF-21. FGF-21 has been previously shown to lower
blood glucose levels in several diabetic rodent and monkey
models [41, 42], to regulate lypolisis in white adipose tissue
[43, 44] and substrate utilization in the liver [45]. FGF-21 was
also shown to directly enhance skeletalmuscle glucose uptake
[46]. The metabolic effects of FGF-21 on glucose metabolism
involve selective regulation by different PPAR isoforms.
Liver-derived FGF-21 is stimulated by PPAR-𝛼 ligands [47].
Conversely, PPAR-𝛾 activation with feeding promotes FGF-
21 production in adipocytes but not in liver [48, 49]. To
our knowledge, this is the first paper that demonstrates a
correlation between PPAR-𝛿 activation and increased FGF-
21 levels in skeletal muscle, thus adding an original piece of
evidence to the complex mechanisms by which PPAR-𝛿 can
regulate several biological functions. Our observation is also
in keeping with a previous study showing that circulating
FGF-21 levels consistently increase in human subjects in
response to pharmacological activation of PPAR-𝛿 [50].
Although a previous investigation has revealed that PPAR-𝛾
directly regulates expression of the FGF-21 gene through ele-
ments located within the 500-bp upstream region of the gene
[49], to date, a consensus sequence of PPAR-𝛿 binding site
in the promoter region of the FGF-21 gene has not yet been
identified. Besides in vitro experiments with FGF-21, small
interfering RNA are warranted to clarify whether GW0742
beneficial effects are related to the direct modulation of
FGF-21 biological functions. The recent findings on FGF-
21 ability to prevent insulin resistance in human myoblasts
by inhibiting NF-𝜅B activation [51] may also suggest that
the muscle-derived FGF-21 acts in an autocrine fashion to
amplify PPAR-𝛿 inhibitory effects on the expression of NF-
𝜅B-dependent inflammatory genes.This further supports the
existence ofmultiple anti-inflammatory pathways involved in
the beneficial effects evoked by PPAR-𝛿 activation.
In conclusion, we have shown that feeding mice with
a HFCS diet for 30 weeks evoked skeletal muscle insulin
resistance and lipid accumulationwhich were associated with
activation of inflammatory pathways. All these effects were
attenuated by selective PPAR-𝛿 activation. In addition, this
study, showing a strong induction of FGF-21 in the skeletal
muscle after chronic administration of the PPAR-𝛿 ligand
GW0742, enhances our knowledge of the mechanisms of
action of PPAR-𝛿 agonism and provides further insights
into the role of FGF-21 as mediator of the tissue cross-
talk that underlines the integrated control of the metabolic
inflammation.
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